|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: PSMA & PSA Targeted Therapy
La Merie Publishing, Jan 2010, Pages: 18
The present Competitive Intelligence Report about PSMA & PSA Targeted Therapy provides a competitor evaluation in the field of molecules targeting prostate specific membrane antigen (PSMA) or prostate specific antigen (PSA) as of January 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy. PSMA represents an attractive antigen for antibody-based diagnostic and therapeutic intervention in prostate cancer, since it is highly restricted to the prostate and overexpressed in all tumor stages. Recently, PSMA has also been found to be expressed in the neovasculature of multiple nonprostatic solid tumors. In addition to the treatment modality antibodies, vaccines including dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer, and PSMA fulfils the requirements for a tumor-associated antigen to be clinically effective. These findings have spurred development of PSMA-targeted therapies for cancer, and first-generation products have entered clinical testing.
Biologic and clinical effects were seen in a small fraction of patients and at doses near the maximum tolerated dose. The initial studies provided proof of concept for PSMA-based therapies. New or improved technologies such as antibody-based drug conjugates or dendritic cell based immunotherapies enabled second-generation antibody and vaccine products which have the promise to exploit PSMA for molecularly targeted therapy of prostate and other cancers.
Prostate-specific antigen (PSA) was discovered more than 20 years ago and has become the premier tumor marker for diagnosis, monitoring and prognosis of prostatic carcinoma despite its very controversially discussed relevance. Similar to PSAM, PSA serves as a molecular target for novel active and passive immunotherapies currently under investigation
The report includes a compilation of currently active projects in research and development of small molecules, antibodies, proteins, cells and vaccines targeting PSMA or PSA for imaging, treatment and monitoring of cancer. In addition, the report lists company-specific R&D pipelines of PSMA & PSA targeted therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Personalized Medicine - Scientific and Commercial Aspects
Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
Future Oncology
Cancer Bundle
Cancer Cell Therapy Markets
Prostate Cancer Therapeutics - Global Strategic Business Report
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
|
|
|
|
